#### Uniprot to Pfam mapping ####
#### UnpAccession: accession of the Uniprot entry ####
#### UnpId : id of the Uniprot entry ####
#### UnpDescription : short description of UniProt entry ####
#### Organism : scientific name of the source organism ####
#### PfamId : id of Pfam family ####
#### PfamName : name of Pfam family ####
#### PfamDescription : short description of Pfam family ####
#### UnpRangeStart, UnpRangeEnd : starting and ending indices in UniProt sequence for the Pfam domain mapping ####
#UnpAccession	UnpId	UnpDescription	Organism	PfamId	PfamName	PfamDescription	UnpRangeStart	UnpRangeEnd
Q8NEB9	PHOSPHATIDYLINOSITOL 3-KINASE CATALYTIC SUBUNIT TYPE 3	PK3C3_HUMAN	Homo sapiens	PF00613	PI3Ka	Phosphoinositide 3-kinase family, accessory domain (PIK domain)	284	530
Q8NEB9	PHOSPHATIDYLINOSITOL 3-KINASE CATALYTIC SUBUNIT TYPE 3	PK3C3_HUMAN	Homo sapiens	PF00792	PI3K_C2	Phosphoinositide 3-kinase C2	53	198
Q8NEB9	PHOSPHATIDYLINOSITOL 3-KINASE CATALYTIC SUBUNIT TYPE 3	PK3C3_HUMAN	Homo sapiens	PF00454	PI3_PI4_kinase	Phosphatidylinositol 3- and 4-kinase	689	833
Q8NEB9	PHOSPHATIDYLINOSITOL 3-KINASE CATALYTIC SUBUNIT TYPE 3	PK3C3_HUMAN	Homo sapiens	PF00454	PI3_PI4_kinase	Phosphatidylinositol 3- and 4-kinase	630	702
#### Uniprot to PDB mapping ####
#### UnpAccession : accession of the UniProt entry ####
#### UnpRangeStart, UnpRangeEnd : starting and ending indices in UniProt sequence corresponding to the PDB residue range ####
#### PDBid : PDB entry id to which the PDB residue range belongs ####
#### PDBtitle : Title of the PDB entry id ####
#### PDBseqStart, PDBseqEnd : starting and ending indices in sequence of the PDB chain (SEQRES record) containing the mapped PDB residues ####
#### PDBchain : PDB chain identifier of the PDB residues mapped to UniProt range ####
#### PDBresidueNumberStart, PDBresidueNumberEnd : starting and ending residue numbers in PDB file for this mapping - sometimes the might contain an insertion code, e.g. 40:A ####
#UnpAccession	UnpRangeStart	UnpRangeEnd	PDBid	PDBtitle	PDBseqStart	PDBseqEnd	PDBchain	PDBresidueNumberStart	PDBresidueNumberEnd
#29 mappings in 23 PDB chains in 14 PDB entries
Q8NEB9	244	258	6hog	Structure of VPS34 LIR motif bound to GABARAP	1	15	A	None	None
Q8NEB9	262	262	6hog	Structure of VPS34 LIR motif bound to GABARAP	18	18	A	1	1
Q8NEB9	244	258	6hoh	Structure of VPS34 LIR motif (S249E) bound to GABARAP	1	15	B	-16	-2
Q8NEB9	244	258	6hoh	Structure of VPS34 LIR motif (S249E) bound to GABARAP	1	15	D	None	None
Q8NEB9	244	258	6hoh	Structure of VPS34 LIR motif (S249E) bound to GABARAP	1	15	C	None	-2
Q8NEB9	244	258	6hoh	Structure of VPS34 LIR motif (S249E) bound to GABARAP	1	15	A	None	-2
Q8NEB9	262	262	6hoh	Structure of VPS34 LIR motif (S249E) bound to GABARAP	18	18	D	1	1
Q8NEB9	262	262	6hoh	Structure of VPS34 LIR motif (S249E) bound to GABARAP	18	18	A	1	1
Q8NEB9	262	262	6hoh	Structure of VPS34 LIR motif (S249E) bound to GABARAP	18	18	B	1	1
Q8NEB9	262	262	6hoh	Structure of VPS34 LIR motif (S249E) bound to GABARAP	18	18	C	1	1
Q8NEB9	268	879	3ls8	Crystal structure of human PIK3C3 in complex with 3-[4-(4-Morpholinyl)thieno[3,2-d]pyrimidin-2-yl]-phenol	3	614	A	None	None
Q8NEB9	268	879	3ls8	Crystal structure of human PIK3C3 in complex with 3-[4-(4-Morpholinyl)thieno[3,2-d]pyrimidin-2-yl]-phenol	3	614	B	None	None
Q8NEB9	268	686	6i3u	Optimization of potent and selective ATM inhibitors suitable for a proof-of-concept study in Huntington's disease models	3	421	A	None	686
Q8NEB9	687	879	6i3u	Optimization of potent and selective ATM inhibitors suitable for a proof-of-concept study in Huntington's disease models	423	615	A	688	None
Q8NEB9	282	879	4uwk	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors	4	601	A	None	None
Q8NEB9	282	879	4uwl	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors	4	601	A	None	None
Q8NEB9	282	879	5anl	Crystal structure of VPS34 in complex with (2S)-8-((3R)-3- Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3, 4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one, processed with the CrystalDirect automated mounting and cryo-cooling technology	4	601	A	None	None
Q8NEB9	282	879	3ihy	Human PIK3C3 crystal structure	3	600	A	282	None
Q8NEB9	282	879	3ihy	Human PIK3C3 crystal structure	3	600	D	None	None
Q8NEB9	282	879	3ihy	Human PIK3C3 crystal structure	3	600	E	282	None
Q8NEB9	282	879	3ihy	Human PIK3C3 crystal structure	3	600	B	282	None
Q8NEB9	282	879	3ihy	Human PIK3C3 crystal structure	3	600	C	282	None
Q8NEB9	282	879	4oys	CRYSTAL STRUCTURE OF VPS34 IN COMPLEX WITH SAR405.	4	601	A	None	None
Q8NEB9	282	879	4uwg	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors	4	601	A	None	None
Q8NEB9	282	879	4uwf	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors	4	601	A	None	None
Q8NEB9	282	879	4uwh	Discovery of (2S)-8-((3R)-3-Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one: a Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors	4	601	A	None	None
Q8NEB9	293	887	5enn	The crystal structure of Human VPS34 in complex with a selective and potent inhibitor	31	625	A	293	None
Q8NEB9	293	887	5enn	The crystal structure of Human VPS34 in complex with a selective and potent inhibitor	31	625	B	293	None
Q8NEB9	293	887	4ph4	The crystal structure of Human VPS34 in complex with PIK-III	31	625	B	293	None

